For most patients, definitive treatment with combined modality therapy is recommended. (HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

These outcomes not only underscore the great potential of the combination therapy of Tyvyt and Elunate but also bring new hope to previously treated patients with advanced renal cell carcinoma ... for ...

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective ...

which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC.

Of the various RCC subtypes, translocation RCC and nonclear cell RCC are the ones most likely to be diagnosed in teenagers. Renal medullary ... such as targeted drug therapy and immunotherapy ...

Radiation-related bowel toxicity among real-world patients was lower with use of the rectal spacer. Use of a hydrogel rectal spacer reduces the incidence of bowel disorders and related procedures ...

It includes medical oncology (the use of chemotherapy, hormone therapy, and other drugs to treat cancer), radiation oncology ... cancer vaccines for renal cell carcinoma with breakthrough results ...

For most patients, definitive treatment with combined modality therapy is ... 27 in Practical Radiation Oncology, evidence-based recommendations are presented to address indications for definitive ...